Clinical trial

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

NCT05555212

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention QLH11811 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-10-25

PhasePHASE1

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

QLH11811DRUG

Sponsors & collaborators

Qilu Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05555212 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.